Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Females of childbearing potential are on approved birth control method~* Negative pregnancy testing for females of childbearing potential~* Previously diagnosed or newly diagnosed with T2DM drug naïve subjects~* HbA1c: 6.7-10%~* Age 18 - 80 years~* BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2~* Fasting serum glucose \< 300 mg/dL~* Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease~* Normal TSH~* On stable diet and exercise routine for at least 4 weeks prior to screening~* Has had a stable weight (+/-5%) for ≥3 months before screening~Exclusion Criteria:~* A history of type 1 diabetes mellitus or history of diabetic ketoacidosis~* History of chronic (required daily for \> 2 months) use of insulin therapy~* Treatment with blood pressure lowering therapy that has not been stable for three months before screening~* Treatment with lipid lowering medication other than statins~* Treatment with statins that has not been stable for three months before screening~* Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time~* Treatment with a thiazolidinedione (TZD) within the last 6 months of screening~* History of an allergic or toxic reaction to sitagliptin or colesevelam~* History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders~* History of major gastrointestinal surgery~* History of kidney problems~* Fasting plasma triglycerides \> 300 mg/dL~* Serum LDL-C \<60 mg/dL~* Positive toxicology test~* Known hypersensitivity to colesevelam HCl or sitagliptin.~* Any contraindications to a study medication (colesevelam HCl or sitagliptin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam HCl: 3 tablets, 2x/day (Type: ACTIVE_COMPARATOR): Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
- Colesevelam plus Sitagliptin (Type: ACTIVE_COMPARATOR): Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).